AIDS-related primary central nervous system lymphoma
diseaseOn this page
Also known as AIDS related lymphoma of primary central nervous systemAIDS related lymphoma of the primary central nervous systemAIDS related primary central nervous system lymphomaAIDS related primary CNS lymphomaAIDS-related lymphoma of primary central nervous systemAIDS-related lymphoma of the primary central nervous systemAIDS-related primary CNS lymphoma
Summary
AIDS-related primary central nervous system lymphoma (MONDO:0006078) is a cancer and 9 clinical trials. Top therapeutic interventions include topotecan hydrochloride, yttrium y 90 ibritumomab tiuxetan, and cilengitide. A subtype of lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | AIDS-related primary central nervous system lymphoma |
| Mondo ID | MONDO:0006078 |
| EFO | EFO:1000077 |
| NCIT | C8284 |
| UMLS | C0281241 |
| MedGen | 79263 |
| GARD | 0024284 |
| Is cancer (heuristic) | yes |
Also known as: AIDS related lymphoma of primary central nervous system · AIDS related lymphoma of the primary central nervous system · AIDS related primary central nervous system lymphoma · AIDS related primary CNS lymphoma · AIDS-related lymphoma of primary central nervous system · AIDS-related lymphoma of the primary central nervous system · AIDS-related primary CNS lymphoma
Disease family
This is a subtype of lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › AIDS-related primary central nervous system lymphoma
Related subtypes (26): prostate lymphoma, nasal cavity lymphoma, bladder lymphoma, tracheal lymphoma, retroperitoneal lymphoma, ureteral lymphoma, ovarian lymphoma, B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, pediatric lymphoma, adult lymphoma, breast lymphoma, heart lymphoma, chest wall lymphoma, lung lymphoma, mediastinal malignant lymphoma, eye lymphoma, B-cell neoplasm, gastrointestinal lymphoma, Hodgkins lymphoma, peripheral T-cell lymphoma, not otherwise specified, composite lymphoma, primary organ-specific lymphoma, non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, methotrexate-associated lymphoproliferative disorders, progressive transformation of germinal centers
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 6 |
| PHASE2 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00005811 | PHASE2 | COMPLETED | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment |
| NCT00267865 | PHASE2 | COMPLETED | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma |
| NCT00003970 | PHASE1 | COMPLETED | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
| NCT00004241 | PHASE1 | COMPLETED | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
| NCT00025415 | PHASE1 | COMPLETED | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
| NCT00036855 | PHASE1 | TERMINATED | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma |
| NCT00077155 | PHASE1 | COMPLETED | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
| NCT01158274 | PHASE1 | COMPLETED | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
| NCT00112593 | Not specified | COMPLETED | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TOPOTECAN HYDROCHLORIDE | 4 | 1 |
| YTTRIUM Y 90 IBRITUMOMAB TIUXETAN | 4 | 1 |
| CILENGITIDE | 3 | 1 |
| INDIUM IN 111 IBRITUMOMAB TIUXETAN | 3 | 1 |
| TANESPIMYCIN | 3 | 1 |
| CHEMBL4786163 | 0 | 1 |